Mirtazapin Neuraxpharm (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine. It also antagonizes certain serotonin receptors (5‑HT2 and 5‑HT3) and strongly blocks H1 histamine receptors, resulting in enhanced serotonergic and noradrenergic neurotransmission and a calming, mood‑lifting effect.

The appropriate dose of Mirtazapin Neuraxpharm is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Dosage adjustments are made according to clinical judgment and patient needs.

Safety data for mirtazapine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers usually consider alternative treatments for pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs). It often causes more sedation and weight gain but may be preferred when patients experience insomnia or poor appetite, whereas SSRIs are generally more activating.

Mirtazapin Neuraxpharm should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and store them out of reach of children.

The medication is taken orally, usually once daily in the evening due to its sedative effect. It should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious risks include the potential for agranulocytosis, severe skin reactions such as Stevens‑Johnson syndrome, significant weight gain, and the emergence or worsening of suicidal thoughts, especially during the initial treatment period. Patients should be monitored closely for any of these events.

Mirtazapin Neuraxpharm is contraindicated in patients who have taken monoamine oxidase inhibitors within the past 14 days, those with known hypersensitivity to mirtazapine, and individuals with severe hepatic impairment. Caution is also advised for patients with a history of bipolar disorder or uncontrolled hypertension.